Strategic partnerships Opportunity: RedHill has active collaboration tracks including Talicia with Cumberland Pharmaceuticals and a global licensing deal for RHB-102 with Hyloris, indicating openness to co-development and regional commercialization partnerships to expand market reach.

Geographic expansion Opportunity: RedHill operates US commercial efforts from Raleigh with a diverse international management team. Potential sales upside through regional licensing deals, distributor partnerships, or joint ventures to accelerate access in Europe, Middle East and other regions.

Pipeline leverage Opportunity: A portfolio of advanced-stage GI and infectious disease candidates provides cross-sell potential with GI-focused clinicians, suggesting customer outreach to specialty pharmacies, hospitals, and gastroenterology networks for trial enrollment and early-access programs.

Rare disease focus Opportunity: FDA rare pediatric disease designation for opaganib in neuroblastoma signals regulatory tailwinds and potential for pediatric oncology collaborations, payer discussions, and specialized hospital network outreach.

Infectious disease strategy Opportunity: Talicia and other GI/infectious disease products position RedHill to engage infectious disease and GI care pathways, pursue formulary placements, and create bundled solutions with antimicrobial stewardship programs in hospitals and clinics.